An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -51,321 | -64,732 | -40,956 | -21,543 | -13,603 |
| Depreciation Amortization | -3,279 | -2,855 | -692 | 53 | N/A |
| Accounts payable and accrued liabilities | 641 | 553 | 2,497 | 417 | 81 |
| Other Working Capital | -3,121 | 5,168 | 3,718 | 32 | 1,224 |
| Other Operating Activity | 7,823 | 8,578 | 1,971 | 557 | 6,934 |
| Operating Cash Flow | $-49,257 | $-53,288 | $-33,462 | $-20,484 | $-5,364 |
| Cash Flows From Investing Activities | |||||
| Purchase Of Investment | -46,751 | -132,178 | -93,836 | -77,274 | N/A |
| Sale Of Investment | 101,340 | 88,900 | 72,065 | 27,250 | N/A |
| Investing Cash Flow | $54,589 | $-43,278 | $-21,771 | $-50,024 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 372 | 84,994 | 70,366 | 11 | 64 |
| Common Stock Repurchased | N/A | N/A | -11 | N/A | N/A |
| Other Financing Activity | 0 | 0 | 0 | 78,524 | 3,772 |
| Financing Cash Flow | $372 | $84,994 | $70,355 | $78,535 | $3,836 |
| Beginning Cash Position | 15,647 | 27,219 | 12,097 | 4,070 | 5,598 |
| End Cash Position | 21,351 | 15,647 | 27,219 | 12,097 | 4,070 |
| Net Cash Flow | $5,704 | $-11,572 | $15,122 | $8,027 | $-1,528 |
| Free Cash Flow | |||||
| Operating Cash Flow | -49,257 | -53,288 | -33,462 | -20,484 | -5,364 |
| Free Cash Flow | -49,257 | -53,288 | -33,462 | -20,484 | -5,364 |